Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer affecting patients worldwide and accounts for 2% of cancer cases in the United Kingdom [1,2]. Incidence is rising and it is associated with several known risk factors including heavy alcohol consumption, non-alcoholic steatohepatitis and chronic hepatitis B and C infection [3,4]. If detected at an early stage, HCC is potentially curable. Unfortunately, many patients are diagnosed at an advanced stage (according to the Barcelona Clinic Liver Cancer criteria) and treatment is therefore palliative focusing on prolonging survival and improving symptom burden. In the advanced setting, sorafenib is recommended as first line option in patients who cannot benefit from resection, transplantation, ablation or transarterial chemoembolization (TACE), and who still have preserved liver function [5]. Sorafenib is the only drug that has shown a significant survival benefit in the last decade. It is a multi-kinase inhibitor with particular action against VEGFR2, PDGFR, FGFR1, Raf-1, B-Raf and c-Kit receptors [6].

In 2008 and 2009, the SHARP and Asia-Pacific trials demonstrated a significant survival benefit for sorafenib versus placebo of 2.8 months and 2.3 months [7,8]. The toxicity profile was acceptable and on the basis of these studies, sorafenib was licenced for use in advanced HCC in many countries including Scotland. Since then, several agents have failed to show superiority or non-inferiority when compared to Sorafenib in the first-line setting [9], with only a handful having an impact on survival. Sorafenib therefore remains the current mainstay of treatment worldwide and at our institution. As trial populations are recognised to not always be representative of a real-world population [10], we sought to determine whether the experience at our institution correlated with the results reported by the SHARP and Asia-Pacific studies.

Results and Discussion

We retrospectively identified 55 patients at our institution who received sorafenib between November 2016 and October 2017. Baseline demographic data were recorded, and electronic patient records were reviewed for duration of treatment, treatment tolerance and survival data. In our study population, 55 patients received sorafenib during the time period. The demographics compared to the SHARP study are shown in Table 1. 46 (84%) were male and 9 (16%) female. The median age was 68 (Range 37-84). All patients were Childs-Pugh A. On starting treatment, performance status (PS) was 0 in 49%, 1 in 47% and 2 in 4%. At the time of analysis, 22 (40%) patients were still alive and 7 (13%)
patients were 3 with a median duration of treatment of 5.8m (95% CI: 2.0m-9.6m). Sorafenib was stopped due to toxicity in 11 (20%) patients, compared to 38% reported in SHARP. The median overall survival was 10.4m (95% CI: 5.6m-15.2m), with no significant difference between PS 0 and PS 1 (11.1m v 9.8m, p=0.8). There was no association between baseline alpha-fetoprotein and survival. Overall, the patients treated with sorafenib at our institution appeared to have similar duration of treatment and overall survival compared to that reported in SHARP (Tables 1 & 2). The obvious limitations in this study are the small numbers and the retrospective nature. Nevertheless, the two populations appear to have broadly similar baseline characteristics and the comparable duration of treatment and overall survival is encouraging, supporting the use of sorafenib in our West of Scotland population.

Table 1: Demographic data in our West of Scotland population (WoS) compared to the SHARP study population.

<table>
<thead>
<tr>
<th></th>
<th>WoS (n=55)</th>
<th>SHARP (n=299)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>84%</td>
<td>87%</td>
</tr>
<tr>
<td>Female</td>
<td>16%</td>
<td>13%</td>
</tr>
<tr>
<td>Age</td>
<td>68 (range 37-84)</td>
<td>64.9</td>
</tr>
<tr>
<td>PS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>49%</td>
<td>54%</td>
</tr>
<tr>
<td>1</td>
<td>47%</td>
<td>38%</td>
</tr>
<tr>
<td>2</td>
<td>4%</td>
<td>8%</td>
</tr>
<tr>
<td>Median cycles of sorafenib completed</td>
<td>5 (range 0-56)</td>
<td>5</td>
</tr>
</tbody>
</table>

Table 2: Median duration of treatment (DoT) and median overall survival (OS) in our population compared to the SHARP population. (m) = months.

<table>
<thead>
<tr>
<th></th>
<th>WoS (n=55)</th>
<th>SHARP (n=299)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median DoT</td>
<td>5.8m (2.0-9.6)</td>
<td>5.3m (NR)</td>
</tr>
<tr>
<td>Median OS</td>
<td>10.4m (5.6-15.2)</td>
<td>10.7m (9.4-13.3)</td>
</tr>
</tbody>
</table>

As mentioned in the introduction, little progress has been made in the treatment of advanced HCC since the SHARP trial. Multiple agents targeting various pathways have been tested unsuccessfully in the first line including multikinase inhibitors (brivanib, sunitinib and linifanib [11-13], anti-EGFR agents (Erlotinib) [14] and cytotoxics such as doxorubicin, 5-flurouracil and oxaliplatin [15,16]. There is therefore an obvious need for patients who are unable to tolerate, or progress on sorafenib therapy to have treatment options. This need has prompted investigation of several agents as first- or second-line treatment options for advanced HCC, with varying degrees of success in recent years. The multi-kinase inhibitors lenvatinib, regorafenib and carbozantinib have all shown significant promise. Of note, they all have similar modes of action to sorafenib. In the REFLECT study, lenvatinib was the first drug to show non-inferiority to sorafenib in the first line setting with a mOS of 13-6 months (95% CI 12.1-14.9) versus 12-3 months, 10-4-13-9; hazard ratio 0.92, 95% CI 0.79-1.06) [17], while in the RESOURCE study regorafenib showed a survival advantage over placebo following progression on sorafenib. Median survival was 10-6 months (95% CI 9.1-12.1) for regorafenib versus 7-8 months (95% CI 6-3-8-8) for placebo [18]. A further multi-kinase inhibitor, carbozantinib is currently being tested in the Phase III CELESTIAL trial following promising Phase II results [19].

Unfortunately, other novel agents have been less successful including the mTOR inhibitor everolimus, the anti-metabolite ADI-PEG20 and the anti-angiogenic Ceditanib (AZD2171) [20-22]. With multi-kinase inhibitors being the main success stories in the treatment of HCC, the emergence of immune checkpoint inhibitors has sparked interest in a new mechanism to target HCC. This is supported by preliminary results from a Phase I/II study of nivolumab, reporting a partial response rate of 19% and 1-year OS of 62% [23]. The study is ongoing, and the results are eagerly anticipated. If the results from other tumour sites are replicated in advanced HCC, it could herald a new and exciting treatment landscape.

Conclusion

Sorafenib continues to be the standard of care in advanced HCC. Our real-world data support the findings of the SHARP study and the use of sorafenib in this population. The landscape of HCC treatments may change in the near future with the emergence of immune checkpoint inhibitors.

References


